$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418053665 Filed on October 12, 2018

Income Statement

Concept	2018 Q1	2018	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.390M	$4.498M	$1.010M
YoY Change	31.13%	10.55%	-2.88%
% of Gross Profit
Research & Development	$1.291M	$4.827M	$1.640M
YoY Change	-17.18%	-12.74%	30.03%
% of Gross Profit
Depreciation & Amortization	$168.5K	$671.8K	$166.7K
YoY Change	2.96%	2.61%	2.65%
% of Gross Profit
Operating Expenses	$2.418M	$9.325M	$2.394M
YoY Change	-7.55%	-2.87%	4.19%
Operating Profit	-$2.418M	-$9.325M	-$2.394M
YoY Change	-7.55%	-2.87%	4.19%
Interest Expense	$310.0K	$2.469M	$1.060M
YoY Change	181.82%	216.25%	332.65%
% of Operating Profit
Other Income/Expense, Net	$308.3K	$761.7K	-$403.1K
YoY Change	-158.95%	-208.23%	-153.66%
Pretax Income	-$2.110M	-$8.563M	-$2.797M
YoY Change	-32.78%	-16.9%	80.86%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.110M	-$8.563M	-$2.797M
YoY Change	-32.78%	-16.9%	80.86%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03	-$0.13	-$0.04
Diluted Earnings Per Share	-$659.4K	-$0.13	-$0.04
COMMON SHARES
Basic Shares Outstanding	64.07M shares	64.92M shares	63.34M shares
Diluted Shares Outstanding	64.07M shares	64.92M shares	63.34M shares

Balance Sheet

Concept	2018 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.62M	$7.082M	$12.05M
YoY Change	-34.28%	-53.1%	-37.56%
Cash & Equivalents	$10.62M	$7.082M	$12.05M
Short-Term Investments
Other Short-Term Assets	$330.0K	$240.3K	$240.0K
YoY Change	-44.07%	26.34%	71.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$10.95M	$7.322M	$12.29M
YoY Change	-34.59%	-52.11%	-36.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.99M	$10.84M	$11.03M
YoY Change	-3.51%	-3.81%	-3.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$8.160K	$30.00K
YoY Change	-66.67%	-86.15%	-62.5%
Total Long-Term Assets	$11.39M	$11.22M	$11.44M
YoY Change	-3.8%	-4.17%	-4.02%
TOTAL ASSETS
Total Short-Term Assets	$10.95M	$7.322M	$12.29M
Total Long-Term Assets	$11.39M	$11.22M	$11.44M
Total Assets	$22.34M	$18.55M	$23.73M
YoY Change	-21.83%	-31.32%	-24.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.880M	$330.8K	$1.550M
YoY Change	1609.09%	-30.57%	868.75%
Accrued Expenses	$410.0K	$253.1K	$30.00K
YoY Change	720.0%	644.26%	-41.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$5.160M
YoY Change		-100.0%	-12.69%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.190M	$882.0K	$6.740M
YoY Change	866.67%	-81.1%	6.65%
LONG-TERM LIABILITIES
Long-Term Debt	$4.730M	$0.00	$4.730M
YoY Change	26.81%		34.38%
Other Long-Term Liabilities	$0.00	$0.00	$1.070M
YoY Change	-100.0%	-100.0%	-55.04%
Total Long-Term Liabilities	$4.730M	$0.00	$4.730M
YoY Change	-19.01%	-100.0%	-19.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.190M	$882.0K	$6.740M
Total Long-Term Liabilities	$4.730M	$0.00	$4.730M
Total Liabilities	$3.190M	$882.0K	$7.810M
YoY Change	-48.3%	-86.8%	-36.08%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.15M	$17.66M	$15.92M
YoY Change
Total Liabilities & Shareholders Equity	$22.34M	$18.55M	$23.73M
YoY Change	-21.83%	-31.32%	-24.34%

Cashflow Statement

Concept	2018 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$2.110M	-$8.563M	-$2.797M
YoY Change	-32.78%	-16.9%	80.86%
Depreciation, Depletion And Amortization	$168.5K	$671.8K	$166.7K
YoY Change	2.96%	2.61%	2.65%
Cash From Operating Activities	-$1.300M	-$7.776M	-$1.400M
YoY Change	-36.59%	-1.54%	-46.56%
INVESTING ACTIVITIES
Capital Expenditures	-$140.0K	$241.8K	-$60.00K
YoY Change	40.0%	46.58%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$140.0K	-$241.8K	-$60.00K
YoY Change	40.0%	46.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.300M	-$7.776M	-1.400M
Cash From Investing Activities	-140.0K	-241.8K	-60.00K
Cash From Financing Activities	0.000	0.000
Net Change In Cash	-1.440M	-$7.776M	-1.460M
YoY Change	-54.29%	-1.54%	-44.27%
FREE CASH FLOW
Cash From Operating Activities	-$1.300M	-$7.776M	-$1.400M
Capital Expenditures	-$140.0K	$241.8K	-$60.00K
Free Cash Flow	-$1.160M	-$8.018M	-$1.340M
YoY Change	-40.51%	-0.56%	-48.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	us-gaap	Assets Assets	27002814	USD
CY2018Q2	us-gaap	Assets Assets	18546212	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15099461	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7081771	USD
CY2017Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	190166	USD
CY2018Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	240257	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	15289627	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	7322028	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	383198	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	374929	USD
CY2017Q2	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2018Q2	us-gaap	Security Deposit SecurityDeposit	4647	USD
CY2017Q2	nnvc	Service Agreements ServiceAgreements	55414	USD
CY2018Q2	nnvc	Service Agreements ServiceAgreements	3515	USD
CY2017Q2	us-gaap	Other Assets OtherAssets	58929	USD
CY2018Q2	us-gaap	Other Assets OtherAssets	8162	USD
CY2017Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	135786	USD
CY2018Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	223339	USD
CY2017Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	340695	USD
CY2018Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	107468	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34004	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	253049	USD
CY2017Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2018Q2	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4665518	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	881948	USD
CY2017Q2	us-gaap	Liabilities Liabilities	6680872	USD
CY2018Q2	us-gaap	Liabilities Liabilities	881948	USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101282707	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95382977	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	63307	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	69172	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83692146	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75128691	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	20321942	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	17664264	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27002814	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18546212	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5531708	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5028970	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4069016	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3830531	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	9600724	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	8859501	USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69171740	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63306774	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69171740	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63306774	shares
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4826840	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4498329	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-9600724	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-8859501	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	60955	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62638	USD
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	780767	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	1042470	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332524	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1347748	USD
CY2016	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1427218	USD
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1696318	USD
CY2016	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	541922	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10304490	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10724629	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-703766	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1865128	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	9325169	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-9325169	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	100429	USD
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	185274	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1348247	USD
CY2018	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	359214	USD
CY2018	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2554020	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	761714	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8563455	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-8563455	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8563455	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10304490	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10724629	USD
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64920856	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60102855	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57669472	shares
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64920856	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60102855	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57669472	shares
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	31785867	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	142589	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	82145	USD
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2018Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8011230	USD
CY2017Q2	us-gaap	Land Land	260000	USD
CY2018Q2	us-gaap	Land Land	260000	USD
CY2017Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	48486	USD
CY2018Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	57781	USD
CY2016	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	882386	USD
CY2016	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	158000	USD
CY2016	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	42886	USD
CY2016	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	23048214	USD
CY2017	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	1272110	USD
CY2017	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	201313	USD
CY2017	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	37948	USD
CY2017	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2018	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	524258	USD
CY2018	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	156190	USD
CY2018	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	16770	USD
CY2018	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2018	nnvc	Series Preferred Shares Issued For Debenture Interest SeriesPreferredSharesIssuedForDebentureInterest	314343	USD
CY2017Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2018Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2017Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5466066	USD
CY2018Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5683765	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13776561	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14018383	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2505501	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3177290	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11271060	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10841093	USD
CY2017	us-gaap	Depreciation Depreciation	654685	USD
CY2016	us-gaap	Depreciation Depreciation	651275	USD
CY2018	us-gaap	Depreciation Depreciation	671789	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	84025	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	374929	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	75756	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	383198	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.23
CY2017Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	150000	shares
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5833	pure
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-10304490	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10724629	USD
CY2017	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	1272110	USD
CY2016	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	882386	USD
CY2018	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	524258	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	328458	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	345589	USD
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	266906	USD
CY2017	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-607178	USD
CY2016	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-660000	USD
CY2018	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-60274	USD
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8269	USD
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8270	USD
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8269	USD
CY2017	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1696318	USD
CY2016	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	541922	USD
CY2018	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2554020	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1347748	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1427218	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	359214	USD
CY2017	nnvc	Gains Losses On Extinguishment Of Series C Debenture GainsLossesOnExtinguishmentOfSeriesCDebenture	-332524	USD
CY2016	nnvc	Gains Losses On Extinguishment Of Series C Debenture GainsLossesOnExtinguishmentOfSeriesCDebenture	0	USD
CY2018	nnvc	Gains Losses On Extinguishment Of Series C Debenture GainsLossesOnExtinguishmentOfSeriesCDebenture	-1348247	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-29292	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5033	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	50091	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	39262	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	7007	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	87553	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-426759	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	451258	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-233227	USD
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1598	USD
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7087	USD
CY2018	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	219045	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-166667	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-166666	USD
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-41667	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7897746	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6829195	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7775868	USD
CY2018	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	16770	USD
CY2017	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	37948	USD
CY2016	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	42886	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-50767	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-40612	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-46505	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4605000	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5000000	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017Q4	us-gaap	Default Longterm Debt Description Of Violation Or Event Of Default DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	24266	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	332524	USD
CY2018	nnvc	Common Stock Value Issued For Debt Instrument Periodic Interest Payment CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment	125000	USD
CY2014Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.1	pure
CY2018Q2	nnvc	Share Price As Per Redemption Agreement SharePriceAsPerRedemptionAgreement	0.0100	pure
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	158000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	313155	shares
CY2017Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	5864337	USD
CY2018	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	45728	shares
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5500000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	156190	USD
CY2018Q1	nnvc	Series Preferred Share Issued For Debenture Interest Shares Issued SeriesPreferredShareIssuedForDebentureInterestSharesIssued	150000	shares
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	819994	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8017690	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9062724	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7305563	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24162185	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	166667	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	173589	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	1036115	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	241822	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164978	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	476368	USD
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	65716	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2016	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	660000	USD
CY2017	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	607178	USD
CY2018Q2	us-gaap	Deferred Compensation Arrangement With Individual Shares Authorized For Issuance DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance	225000	shares
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	56115	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	nnvc	Preferred Stock Issued For Debentures PreferredStockIssuedForDebentures	0	USD
CY2016	nnvc	Preferred Stock Issued For Debentures PreferredStockIssuedForDebentures	0	USD
CY2018	nnvc	Preferred Stock Issued For Debentures PreferredStockIssuedForDebentures	314343	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5332524	USD
CY2018	nnvc	Warrants Issued For Severance Agreement WarrantsIssuedForSeveranceAgreement	53500	USD
CY2017	nnvc	Warrants Issued For Severance Agreement WarrantsIssuedForSeveranceAgreement	0	USD
CY2016	nnvc	Warrants Issued For Severance Agreement WarrantsIssuedForSeveranceAgreement	0	USD
CY2018	nnvc	Software Disposal Noncash Adjustment SoftwareDisposalNoncashAdjustment	0	USD
CY2017	nnvc	Software Disposal Noncash Adjustment SoftwareDisposalNoncashAdjustment	0	USD
CY2016	nnvc	Software Disposal Noncash Adjustment SoftwareDisposalNoncashAdjustment	26974	USD
CY2018	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2017	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2016	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-3515	USD
CY2018	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2016	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	332476	USD
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"> </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="white-space: pre-wrap; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-wrap; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risk</div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	332476	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8270	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8270	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8270	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8270	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8270	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	333579	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	374929	USD
CY2017Q1	nnvc	Conversion Price Of Shares Converted ConversionPriceOfSharesConverted	1.1533
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
CY2017Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5332524	USD
CY2017Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40393660	USD
CY2016	nnvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	53500	USD
CY2016	nnvc	Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest	56115	USD
CY2017	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2018	us-gaap	Stock Issued1 StockIssued1	125000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
CY2017	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
CY2016	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
CY2018	nnvc	Stock Issued During Period Value Issued For Series C Debentures StockIssuedDuringPeriodValueIssuedForSeriesCDebentures	4730000	USD
CY2016Q1	nnvc	Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest	56115	USD
CY2018Q3	us-gaap	Life Insurance Corporate Or Bank Owned Amount LifeInsuranceCorporateOrBankOwnedAmount	2000000	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016	nnvc	Fair Value Measurement Significant Assumptions FairValueMeasurementSignificantAssumptions	a. The common stock price was in the range $1.82 to $1.20; b.The calculated weighted average number of shares of common stock in the period; c.A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years; f. 30.86% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.52% to 69.38% volatility, 0.22% to 0.26% risk free rate) applied to the converted common.
CY2017	nnvc	Fair Value Measurement Significant Assumptions FairValueMeasurementSignificantAssumptions	a.The common stock price was in the range $1.07 to $1.74; b. The calculated weighted average number of shares of common stock in the period; c. A 26.63% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 10.25% to 12.26% of the total; e. The conversion value was based on an assumption for calculation purposes only, for the period ended September 30, 2016 of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years. For the period from October 1, 2016 to June 30, 2017, the conversion value was based on an assumption for calculation purposes only of a Change of Control in 4 years and a remaining restricted term of 4 to 3.34 years; f. 1.76% to 38.87% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.58% to 85.39% volatility, 0.37% to 1.50% risk free rate) applied to the converted common.
CY2018	nnvc	Fair Value Measurement Significant Assumptions FairValueMeasurementSignificantAssumptions	a. The common stock price was in the range $.58 to $1.14; b. The calculated weighted average number of shares of common stock in the period; c. A 26.63% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 10.25% to 15.50% of the total; e. The conversion value was based on an assumption for calculation purposes only, for the period ended September 30, 2016 of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years. For the period from October 1, 2016 to June 30, 2017, the conversion value was based on an assumption for calculation purposes only of a Change of Control in 4 years and a remaining restricted term of 4 to 3.34 years; f. 21.76% to 38.87% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 53.22% to 85.39% volatility, 0.37% to 2.10% risk free rate) applied to the converted common.
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4730000	USD
CY2018Q2	us-gaap	Share Price SharePrice	1.14
CY2018	nnvc	Warrant Term WarrantTerm	P5Y
CY2017	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Shares CommonStockIssuedDuringPeriodSettlementOfAccountsPayableShares	71430	shares
CY2017	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Value CommonStockIssuedDuringPeriodSettlementOfAccountsPayableValue	82145	USD
CY2017Q1	nnvc	Restricted Common Stock Value Debt Instrument RestrictedCommonStockValueDebtInstrument	5000000	USD
CY2017	nnvc	Restricted Common Stock Shares Number Of Shares Authorized For Issuance RestrictedCommonStockSharesNumberOfSharesAuthorizedForIssuance	107178	shares
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16770	USD
CY2018	nnvc	Restricted Common Stock Shares Number Of Shares Authorized For Issuance RestrictedCommonStockSharesNumberOfSharesAuthorizedForIssuance	5000000	shares
CY2017Q4	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2017	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4730000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24839394	USD
CY2017Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23839852	USD
CY2018Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6198377	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6217612	USD
CY2018Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6047301	USD
CY2017Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10336196	USD
CY2018Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37085072	USD
CY2017Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40393660	USD
CY2018Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37085072	USD
CY2017Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40393660	USD
CY2018Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018	nnvc	Adjustment Of Warrants Granted As Compensation AdjustmentOfWarrantsGrantedAsCompensation	53500	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Shares CommonStockIssuedDuringPeriodSettlementOfAccountsPayableShares	71430	shares
CY2018	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Value CommonStockIssuedDuringPeriodSettlementOfAccountsPayableValue	65716	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2810	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3087	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.4582	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.4628	pure
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1 – Organization and Nature of Business</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;">NanoViricides, Inc. (the Company”) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="font: 10pt "times new roman", times, serif; margin: 0px; text-align: justify; background: none;">We are a company with several drugs in various stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide™ program alone, we have drug candidates against at least five indications at different stages of development. Of these, our shingles drug candidate is expected to enter human clinical trials in the very near future. It is in advanced, IND-enabling pre-clinical studies at present, and large-scale production is being performed to supply the safety-toxicology study. In addition, our drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). Chickenpox is re-emerging as a major disease especially in European countries, with 23,500 confirmed cases in the first six months of 2018. In addition, we have drugs in development against all influenzas in our FluCide™ program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font: 10pt "times new roman", times, serif; margin: 0px; text-align: justify; background: none;">Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have broad, exclusive licenses in perpetuity. The first license agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  In addition, the Company is negotiating a license for VZV (shingles, chicken pox virus), and the remaining human herpes viruses from TheraCour. For this purpose, the Company has conducted a valuation for the shingles and PHN indications. The negotiation process has begun in earnest after the reporting period, with Dr. Irach Taraporewala being appointed as the new Chief Executive Officer of the Company, effective September 1, 2018. To date, TheraCour has not withheld any licenses for antiviral nanomedicines that NanoViricides has asked for, and we anticipate that the licenses to the remaining herpes viruses including VZV will be executed once the due diligence process is completed.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	233333	USD
CY2017Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	0	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19716	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29141	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4863	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	253049	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34004	USD
CY2018Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37085072	USD
CY2018Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	70000000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0040	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0687	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0610	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0379	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0495	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0618	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.6236	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q4	dei	Entity Public Float EntityPublicFloat	37865000	USD
CY2018	dei	Trading Symbol TradingSymbol	NNVC
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69383000	shares
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2018	nnvc	Percentage Of Net Sales Allocated For Royalty Payments PercentageOfNetSalesAllocatedForRoyaltyPayments	0.15	pure
CY2018	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	costs (direct and indirect) plus no more than 30% of certain direct costs
CY2018	us-gaap	Default Longterm Debt Description Of Violation Or Event Of Default DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;

Files In Submission

Name	View Source	Status
0001144204-18-053665-index-headers.html	Edgar Link	pending
0001144204-18-053665-index.html	Edgar Link	pending
0001144204-18-053665.txt	Edgar Link	pending
0001144204-18-053665-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20180630.xml	Edgar Link	completed
nnvc-20180630.xsd	Edgar Link	pending
nnvc-20180630_cal.xml	Edgar Link	unprocessable
nnvc-20180630_def.xml	Edgar Link	unprocessable
nnvc-20180630_lab.xml	Edgar Link	unprocessable
nnvc-20180630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv501564_10k.htm	Edgar Link	pending
tv501564_ex31-1.htm	Edgar Link	pending
tv501564_ex31-2.htm	Edgar Link	pending
tv501564_ex32-1.htm	Edgar Link	pending
tv501564_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2018 Q1 Form 10-K Financial Statement

#000114420418053665 Filed on October 12, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2018 Q1 Form 10-K Financial Statement

#000114420418053665 Filed on October 12, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc